Edition:
United Kingdom

Evolus Inc (EOLS.OQ)

EOLS.OQ on NASDAQ Stock Exchange Global Market

17.36USD
23 May 2018
Change (% chg)

$0.47 (+2.78%)
Prev Close
$16.89
Open
$16.80
Day's High
$17.57
Day's Low
$16.66
Volume
54,008
Avg. Vol
--
52-wk High
$17.85
52-wk Low
$6.78

Latest Key Developments (Source: Significant Developments)

Evolus Announces Update With DWP-450 Regulatory Submissions
Wednesday, 16 May 2018 

May 16 (Reuters) - Evolus Inc ::EVOLUS ANNOUNCES PROGRESS WITH DWP-450 REGULATORY SUBMISSIONS.EVOLUS INC - CONFERENCE CALL SCHEDULED FOR 8:30AM ET / 5:30AM PT.EVOLUS INC - EVOLUS RECEIVES FDA COMPLETE RESPONSE LETTER WITH COMMENTS ISOLATED TO CMC ITEMS.EVOLUS INC - PLANS TO UTILIZE DAEWOONG FACILITY TO SUPPORT COMMERCIAL PRODUCTION FOLLOWING ANTICIPATED APPROVAL OF DWP-450..EVOLUS INC - FDA ISSUES FAVORABLE EIR LETTER RELATED TO MANUFACTURING FACILITY.EVOLUS INC - DWP-450 MANUFACTURING FACILITY IS FULLY VALIDATED BY DAEWOONG UNDER CURRENT GOOD MANUFACTURING PRACTICE REQUIREMENTS.EVOLUS INC - IN CRL, DEFICIENCIES CITED BY FDA WERE ISOLATED TO ITEMS RELATED TO CHEMISTRY, MANUFACTURING, AND CONTROLS PROCESSES.EVOLUS INC - EXPECTS TO RESPOND TO FDA ABOUT CRL WITH A COMPLETE SUBMISSION TO FDA WITHIN 90 DAYS.EVOLUS INC - LOOK FORWARD TO WORKING CLOSELY WITH FDA AND REMAIN COMMITTED TO BRINGING DWP-450 TO MARKET BY SPRING 2019.EVOLUS INC - DWP-450 MANUFACTURING FACILITY HAS CAPACITY EXPECTED TO MEET ANTICIPATED PRODUCT DEMAND.  Full Article

Evolus Reports Q1 Loss Per Share $0.30
Thursday, 10 May 2018 

May 10 (Reuters) - Evolus Inc ::EVOLUS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.30.Q1 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.  Full Article

Evolus Appoints Allergan Aesthetics Head As President And Chief Executive Officer
Monday, 7 May 2018 

May 7 (Reuters) - Evolus Inc ::EVOLUS APPOINTS ALLERGAN AESTHETICS HEAD AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.SAYS DAVID MOATAZEDI APPOINTED CEO AND PRESIDENT.MOATAZEDI WILL SUCCEED MURTHY SIMHAMBHATLA.  Full Article